Evaluating CJC-1295 cost for laboratory applications requires understanding the chemical modifications, analytical validation standards, and manufacturing protocols that drive procurement pricing. As a synthetic growth hormone-releasing hormone (GHRH) analog, CJC-1295 pricing varies based on purity tiers, lot-specific mass spectrometry testing, endotoxin quantification, and whether the peptide includes the Drug Affinity Complex (DAC). This guide provides an objective cost breakdown and quality framework for institutional investigators acquiring research-grade reagents.
Evaluating CJC-1295 cost for laboratory applications requires understanding the chemical modifications, analytical validation standards, and manufacturing protocols that drive procurement pricing. As a synthetic growth hormone-releasing hormone (GHRH) analog, CJC-1295 pricing varies based on purity tiers, lot-specific mass spectrometry testing, endotoxin quantification, and whether the peptide includes the Drug Affinity Complex (DAC). This guide provides an objective cost breakdown and quality framework for institutional investigators acquiring research-grade reagents.
The procurement cost of CJC-1295 for laboratory research ranges based on chemical synthesis scale, purity thresholds (such as ≥98% via RP-HPLC), and the incorporation of the Drug Affinity Complex (DAC) reactive group. Standard non-DAC formulations typically carry lower synthesis expenditures per milligram, whereas DAC-modified CJC-1295 involves specialized bioconjugation chemistry, increasing production complexity and market valuation for preclinical studies.
When budgeting for research peptides, principal investigators must look beyond raw unit cost to evaluate batch-to-batch consistency, third-party analytical verification, and endotoxin compliance. Cheap unverified reagents often contain truncated peptide sequences, residual trifluoroacetic acid (TFA), or bacterial endotoxins that invalidate cell culture and rodent assays, dramatically increasing the true cost of research through failed experiments.
CJC-1295 is a 29-amino-acid tetrasubstituted peptide analog of endogenous growth hormone-releasing hormone (GHRH 1-29). In preclinical models, CJC-1295 acts as a selective GHRH receptor agonist, binding to GHRH receptors expressed on pituitary somatotrophs. This binding cascade triggers intracellular cAMP accumulation and activates protein kinase A (PKA), leading to the transcription and pulsatile secretion of endogenous growth hormone (GH).
Sustained elevation of GH subsequently stimulates hepatic production of insulin-like growth factor 1 (IGF-1). In laboratory models of tissue repair, cellular proliferation, and microvascular regeneration, investigators utilize CJC-1295 to explore how long-acting somatotropic signaling influences nitrogen retention, collagen cross-linking, and skeletal muscle satellite cell activation. For detailed biochemical pathways, researchers can reference the comprehensive literature in our research library.
A primary driver of CJC-1295 cost is whether the compound is synthesized with or without the Drug Affinity Complex (DAC). The DAC modification adds a maleimido-propionic acid reactive group to the Lysine residue at position 30. In animal models, this moiety forms a stable covalent bond with endogenous circulating albumin, extending the peptide's biological half-life from approximately 30 minutes to over 6 to 8 days.
Evaluating CJC-1295 DAC requires accounting for the complex bioconjugation reaction and multi-step purification required during solid-phase peptide synthesis (SPPS). Conversely, CJC-1295 No DAC (also known as Modified GRF 1-29) lacks this albumin-binding motif, resulting in a shorter half-life that mimics physiological GHRH pulses. Because Modified GRF 1-29 requires fewer synthetic additions, its cost per milligram is typically lower, making it ideal for short-duration acute signaling studies.
In vitro and animal studies consistently demonstrate that CJC-1295 provides sustained stimulation of the somatotropic axis. Rodent models evaluating tissue repair mechanisms have shown that prolonged elevation of systemic IGF-1 levels correlates with accelerated cellular turnover in tendon, ligament, and skeletal muscle matrixes. Research published in endocrinology literature notes that continuous GHRH receptor activation via CJC-1295 maintains normal GH pulsatility while elevating base-level GH concentrations.
Furthermore, preclinical investigations into metabolic rate, lipid oxidation, and bone mineral density utilize CJC-1295 to model endocrine signaling in aging or catabolic animal subjects. By sustaining GH and IGF-1 levels without causing pituitary desensitization, CJC-1295 serves as a core benchmark compound in comparative studies involving growth hormone secretagogues.
The market price for research-grade CJC-1295 reflects the rigorous quality assurance protocols employed during production. High-grade synthesis relies on automated solid-phase peptide synthesis (SPPS) using Fmoc chemistry, followed by multiple purification passes using preparative reverse-phase high-performance liquid chromatography (RP-HPLC). Skimping on these steps lowers cost but yields reagents burdened with deletion sequences, stereoisomer impurities, and TFA salts.
To ensure reproducible data in cell culture and preclinical trials, laboratory reagents must meet strict threshold standards: ultra-high purity (≥98%), confirmed molecular identity via Electrospray Ionization Mass Spectrometry (ESI-MS), and low endotoxin levels (<0.01 EU/mg). Sourcing low-cost peptides from unverified vendors risks introducing active contaminants that alter receptor expression, induce cellular toxicity, or trigger non-specific inflammatory pathways in animal models.
When reviewing vendor quotes for CJC-1295 cost, verifying third-party analytical validation is critical. Premium suppliers provide a independent Certificate of Analysis (COA) for every single batch, rather than relying on historical or generic documentation. An authentic COA must include an RP-HPLC chromatogram showing peak area purity, an ESI-MS spectral analysis confirming exact molecular weight, and an LAL assay report detailing endotoxin content.
PX1 Research manufactures all compounds in ISO 17025 accredited and cGMP-compliant facilities within the United States. Every lot undergoes rigorous testing to verify purity and potency before release. Investigators interested in institutional volume sourcing or specialized assay reagents can review options through our wholesale lab portal to secure verified, high-purity inventory with complete lot traceability.
To contextualize CJC-1295 cost within secretagogue research, investigators frequently compare it against alternative GHRH analogs and ghrelin receptor agonists. For instance, Sermorelin represents the un-modified 29-amino-acid chain of endogenous GHRH. While Sermorelin exhibits a rapid clearance rate requiring frequent administration in animal models, CJC-1295 (especially with DAC) provides prolonged receptor occupancy. In terms of expenditure per study duration, CJC-1295 DAC often yields lower total material consumption in long-term rodent experiments.
Additionally, co-administration studies frequently pair CJC-1295 No DAC with selective growth hormone secretagogues like Ipamorelin or GHRP-6. Preclinical data demonstrate that combining a GHRH agonist (such as CJC-1295) with a ghrelin receptor agonist produces a synergistic release of GH from pituitary somatotrophs, significantly exceeding the additive response of either peptide alone. Balancing the material costs of dual-peptide protocols against single-agent studies is a primary consideration in experimental design.
To protect the structural integrity of CJC-1295 and preserve your research investment, proper handling protocols must be enforced inside the laboratory. Lyophilized CJC-1295 is stable at room temperature for short periods during transport but should be stored at -20°C or -80°C upon receipt to prevent thermal degradation over time.
Reconstitution guidelines for in vitro and laboratory assays include the following steps:
1. Allow the lyophilized vial to equilibrate to room temperature before reconstitution to prevent moisture condensation.
2. Reconstitute using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.9% Sodium Chloride, depending on downstream cell culture compatibility.
3. Aim the diluent stream against the glass vial wall rather than directly onto the lyophilized cake to minimize mechanical agitation and foaming.
4. Gently swirl the vial until complete dissolution occurs; never vortex research peptides.
5. Store reconstituted liquid aliquots at 2°C to 8°C for short-term use (up to 30 days) or freeze at -80°C to avoid repeated freeze-thaw cycles.
Institutional laboratories operating under strict grant budgets can optimize CJC-1295 cost through strategic procurement practices. Ordering standardized milligram quantities (e.g., 2mg, 5mg, or 10mg vials) aligned with planned assay schedules minimizes freeze-thaw degradation and reagent loss. Furthermore, establishing multi-vial or bulk procurement agreements through accredited domestic suppliers reduces per-unit shipping and analytical validation expenses.
By sourcing directly from US-based manufacturers like PX1 Research—featuring same-day shipping from California and Arizona facilities—laboratories reduce supply chain downtime, eliminate import customs risks, and guarantee lot-to-lot consistency. Investing in high-purity, fully validated CJC-1295 protects research fidelity, preventing costly experimental re-runs caused by impure or degraded reagents.
What factors influence the cost of CJC-1295 for research laboratories?
CJC-1295 cost is primarily determined by synthesis purity levels (e.g., ≥98%), inclusion of the Drug Affinity Complex (DAC), mass spectrometry and HPLC testing, endotoxin removal processes, and the scale of production.
Why is CJC-1295 with DAC typically more expensive than CJC-1295 without DAC?
CJC-1295 with DAC involves an additional chemical modification (maleimido-propionic acid bioconjugation) that allows it to bind to albumin. This extra synthesis step and specialized purification process increase manufacturing costs relative to standard Modified GRF 1-29.
What analytical documentation should accompany high-quality CJC-1295?
Every research lot should include a third-party Certificate of Analysis (COA) containing RP-HPLC purity profiles, ESI-MS mass verification, and LAL endotoxin testing results.
Is CJC-1295 suitable for human consumption or therapeutic administration?
No. CJC-1295 supplied by PX1 Research is strictly designated for laboratory research use only (RUO) and in vitro / preclinical studies. It is not for human or veterinary consumption, medical treatment, or clinical use.
How does peptide purity impact preclinical experiment costs?
Sub-standard or low-purity peptides often contain truncated amino acid sequences and endotoxins that alter cell culture signaling or induce toxic responses in animal models. Using unverified reagents leads to invalid data and repeated experiments, raising overall project costs.
What is the recommended storage temperature for CJC-1295 powder?
Lyophilized CJC-1295 should be stored at -20°C for medium-term storage or -80°C for long-term preservation to protect the peptide chain from hydrolysis and oxidation.
What diluent should be used to reconstitute CJC-1295 for laboratory assays?
Standard laboratory reconstitution uses sterile bacteriostatic water (0.9% benzyl alcohol) for multi-use assay sampling or sterile 0.9% saline for specific cell culture protocols where preservatives must be avoided.
What is the target endotoxin limit for research-grade CJC-1295?
High-grade research peptides intended for sensitive cellular and animal studies should maintain endotoxin levels below 0.01 EU/mg to prevent non-specific immune cell activation.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.